College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
Department of Pharmacology, College of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada.
Curr Top Med Chem. 2023;23(23):2232-2241. doi: 10.2174/1568026623666230705151922.
Lysergic acid Diethylamide (LSD), psilocybin, and psilocin are being intensively evaluated as potential therapeutics to treat depression, anxiety, substance use disorder, and a host of other psychiatric illnesses. Pre-clinical investigation of these compounds in rodent models forms a key component of their drug development process. In this review, we will summarize the evidence gathered to date surrounding LSD, psilocybin, and psilocin in rodent models of the psychedelic experience, behavioural organization, substance use, alcohol consumption, drug discrimination, anxiety, depression-like behaviour, stress response, and pharmacokinetics. In reviewing these topics, we identify three knowledge gaps as areas of future inquiry: sex differences, oral dosing rather than injection, and chronic dosing regimens. A comprehensive understanding of LSD, psilocybin, and psilocin's in vivo pharmacology may not only lead to their successful clinical implementation but optimize the use of these compounds as controls or references in the development of novel psychedelic therapeutics.
麦角酸二乙酰胺（LSD）、裸盖菇素和二甲氧基安非他命正在被深入评估为治疗抑郁症、焦虑症、物质使用障碍和许多其他精神疾病的潜在疗法。这些化合物在啮齿动物模型中的临床前研究是其药物开发过程的关键组成部分。在这篇综述中，我们将总结迄今为止围绕 LSD、裸盖菇素和二甲氧基安非他命在致幻体验、行为组织、物质使用、酒精消费、药物辨别、焦虑、抑郁样行为、应激反应和药代动力学的啮齿动物模型中的研究证据。在回顾这些主题时，我们确定了三个未来研究的知识空白领域：性别差异、口服给药而非注射给药，以及慢性给药方案。全面了解 LSD、裸盖菇素和二甲氧基安非他命的体内药理学不仅可能导致它们的成功临床应用，而且还可以优化这些化合物作为新型致幻治疗药物的对照或参考物的使用。
